Skip Navigation

JNCI Journal of the National Cancer Institute 2004 96(23):1731-1733; doi:10.1093/jnci/djh345
© 2004 by Oxford University Press
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (4)
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Kalidas, M.
Right arrow Articles by Brown, P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Kalidas, M.
Right arrow Articles by Brown, P.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2004 Oxford University Press

EDITORIAL

Defining the Role of Raloxifene for the Prevention of Breast Cancer

Mamta Kalidas, Susan Hilsenbeck, Powel Brown

Affiliation of authors: Breast Center, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030

Correspondence to: Powel Brown, MD, PhD, Breast Center, Baylor College of Medicine, MS 600, One Baylor Plaza, Houston, TX 77030 (e-mail: pbrown@breastcenter.tmc.edu)

The first 150 words of the full text of this article appear below.

Over the last 5 years, the results of several breast cancer prevention trials have demonstrated the usefulness of anti-estrogen selective estrogen receptor modulators (SERMs) for the prevention of breast cancer. The National Surgical Adjuvant Breast and Bowel Project (NSABP) P-1 breast cancer prevention trial was the first trial to show a major benefit of a SERM: The anti-estrogen SERM tamoxifen reduced the risk of breast cancer in women who were at high risk of the disease by 49% (1). The results of several other breast cancer prevention trials confirmed the cancer-preventive benefit of tamoxifen [reviewed in Cuzick et al. (2)], although the magnitudes of benefit reported in these other trials were lower than that reported by the P-1 trial. Together, these results provide strong support for the use of tamoxifen to reduce the risk of breast cancer in women at high risk of this . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Obstet GynecolHome page
S. C. Willey and C. Cocilovo
Screening and Follow-up of the Patient at High Risk for Breast Cancer
Obstet. Gynecol., December 1, 2007; 110(6): 1404 - 1416.
[Abstract] [Full Text] [PDF]